Diabetes with hypertension medical therapy: Difference between revisions
| Line 6: | Line 6: | ||
==Supportive trial data== | ==Supportive trial data== | ||
'''1)''' Study name - | '''1)''' Study name - '''Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial''' ('''[[FACET]]'''), 1998 | ||
'''2)''' Study design | '''2)''' Study design | ||
| Line 16: | Line 16: | ||
* Exclusion criteria- History of [[coronary heart disease]] or [[stroke]], serum [[creatinine]] > 1.5 mg/dl, [[albuminuria]] > 40 micrograms/min, and use of lipid-lowering drugs, [[aspirin]], or antihypertensive agents other than [[beta-blocker]]s or [[diuretic]]s. | * Exclusion criteria- History of [[coronary heart disease]] or [[stroke]], serum [[creatinine]] > 1.5 mg/dl, [[albuminuria]] > 40 micrograms/min, and use of lipid-lowering drugs, [[aspirin]], or antihypertensive agents other than [[beta-blocker]]s or [[diuretic]]s. | ||
'''3)''' Results- Fosinopril lowered the risk of the composite endpoints of acute [[myocardial infarction]], stroke, or hospitalization due to [[angina]] more compared to amlodipine (hazards ratio = 0.49, 95% CI = 0.26-0.95)<ref name="pmid9571349">{{cite journal| author=Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G et al.| title=Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. | journal=Diabetes Care | year= 1998 | volume= 21 | issue= 4 | pages= 597-603 | pmid=9571349 | doi= | pmc= | url= }} </ref>. | '''3)''' Results- Fosinopril lowered the risk of the composite endpoints of acute [[myocardial infarction]], stroke, or hospitalization due to [[angina]] more compared to amlodipine (hazards ratio = 0.49, 95% CI = 0.26-0.95). However, no significant difference in total [[serum cholesterol]], [[HDL cholesterol]], [[HbA1c]], fasting serum glucose, or plasma insulin was found <ref name="pmid9571349">{{cite journal| author=Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G et al.| title=Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. | journal=Diabetes Care | year= 1998 | volume= 21 | issue= 4 | pages= 597-603 | pmid=9571349 | doi= | pmc= | url= }} </ref>. | ||
==References== | ==References== | ||
Revision as of 14:53, 15 September 2011
|
Diabetes mellitus Main page |
|
Patient Information |
|---|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]; Cafer Zorkun, M.D., Ph.D. [3]
Overview
Hypertension is a common co-morbidity associated with patients of diabetes, especially type 2 diabetes. Proper management of both these conditions are important to prevent future chronic complications like cardiovascular, nephrology and other complications.
Supportive trial data
1) Study name - Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET), 1998
2) Study design
- Open label, randomized trial
- 380 hypertensive diabetics patient
- Fosinopril (20 mg/day) or amlodipine (10 mg/day)
- Follow up 3.5 years
- Inclusion criteria- NIDDM and hypertension (SBP > 140 mmHg or DBP > 90 mmHg).
- Exclusion criteria- History of coronary heart disease or stroke, serum creatinine > 1.5 mg/dl, albuminuria > 40 micrograms/min, and use of lipid-lowering drugs, aspirin, or antihypertensive agents other than beta-blockers or diuretics.
3) Results- Fosinopril lowered the risk of the composite endpoints of acute myocardial infarction, stroke, or hospitalization due to angina more compared to amlodipine (hazards ratio = 0.49, 95% CI = 0.26-0.95). However, no significant difference in total serum cholesterol, HDL cholesterol, HbA1c, fasting serum glucose, or plasma insulin was found [1].